TY - JOUR T1 - Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial JF - medRxiv DO - 10.1101/2021.06.29.21259504 SP - 2021.06.29.21259504 AU - Deborah Cromer AU - Arnold Reynaldi AU - Megan Steain AU - James A Triccas AU - Miles P Davenport AU - David S Khoury Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/30/2021.06.29.21259504.abstract N2 - A recent study analysed the relationship between neutralising antibody response and protection from SARS-CoV-2 infection across eight vaccine platforms1. The efficacy results from a phase 2b/3 trial of a ninth vaccine candidate, CVnCoV (CUREVAC), was announced on 16 June 20212. The low efficacy of this new mRNA vaccine, which showed only 47% protection from symptomatic SARS-CoV-2 infection, was surprising given the high efficacy of two previous mRNA-based vaccines3,4. A number of factors have been suggested to play a role in the low efficacy in the CVnCoV study, particularly around the dose and immunogenicity of the vaccine (which uses an unmodified mRNA construct5,6) and the potential role of infection with SARS-CoV-2 variants (which were the dominant strains observed in the CVnCoV trial)2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by an Australian government Medical Research Future Fund awards GNT2002073, MRF2005544 and MRF2005760 (to MPD), an NHMRC program grant GNT1149990 (MPD), and NHMRC CRE 1153493 (JAT). DSK, DC and MPD are supported by NHMRC Fellowship / Investigator grants.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved under the UNSW Sydney Human Research Ethics Committee (approval HC200242).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code are freely available from the corresponding author upon request. ER -